EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

INM004: Polyclonal Neutralizing Antibodies Against Shiga Toxin as a Treatment for Hemolytic Uremic Syndrome

Marta Rivas, Mariana Pichel, Vanesa Zylberman, Mariana Colonna iD, Marina Valerio, Carolina Massa, Romina Pardo, Andrés E Ciocchini, Santiago Sanguineti, Ian Roubicek, Linus Spatz, Fernando Alberto Goldbaum

Toxins · 2025

DOI: 10.3390/toxins17060282 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxins, 2025. Verfasst von Marta Rivas und 11 weiteren Autor:innen. Beteiligte Einrichtung: Inmunova S.A., Av. 25 de Mayo 1021, San Martín, Buenos Aires 1650, Argentina. Hauptthemen laut MEDLINE: Hemolytic-Uremic Syndrome, Antibodies, Neutralizing, Shiga Toxin, Escherichia coli Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI). Shiga toxin (Stx)-producing Escherichia coli-associated HUS (STEC-HUS) is one of the leading causes of AKI in children. Approximately 1.5 to 3% of children die during the acute phase, and about 30% experience long-term renal sequelae. Argentina has the highest incidence of STEC-HUS globally. Given the prominent role of Stx in its pathophysiology, STEC-HUS is considered more of a toxemia than a bacterial disease. Stx transport occurs before and after the STEC-HUS onset, allowing for the distinction between an early toxemia phase and an advanced toxemia phase. In this review, we present our efforts to develop INM004, an anti-Stx treatment aimed at ameliorating or preventing the clinical consequences of STEC-HUS. We describe the protein engineering that facilitated this development and the clinical path to demonstrate the safety and efficacy of INM004. This immunotherapy could represent a new step in the treatment of STEC-HUS, which could potentially prevent long-term damage. If phase 3 trials are successful, earlier and broader use of INM004 is envisioned. We also discuss the potential impact of INM004 therapy, targeted vaccination strategies, and new diagnostic tools for this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemolytic-Uremic SyndromeAntibodies, NeutralizingShiga ToxinEscherichia coli InfectionsHumansAnimalsShiga-Toxigenic Escherichia coli

Stichwörter der Autor:innen

STEC-HUSShiga toxindiagnosishemolytic uremic syndromeimmunotherapy treatmentvaccine development

Substanzen

Antibodies, NeutralizingShiga Toxin

Autor:innen und Institutionen

  • Inmunova S.A., Av. 25 de Mayo 1021, San Martín, Buenos Aires 1650, Argentina.
  • Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Godoy Cruz 2290, Ciudad Autonoma de Buenos Aires 1425, Argentina.
  • Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM), Escuela de Bio y Nanotecnologías, UNSAM Campus Miguelete, 25 de Mayo y Francia, San Martín 1650, Argentina.

ORCID-Profile: Mariana Colonna

Zitieren

APA

Rivas, M., Pichel, M., Zylberman, V., Colonna, M., Valerio, M., Massa, C., Pardo, R., Ciocchini, A. E., Sanguineti, S., Roubicek, I., Spatz, L., & Goldbaum, F. A. (2025). INM004: Polyclonal Neutralizing Antibodies Against Shiga Toxin as a Treatment for Hemolytic Uremic Syndrome. Toxins. https://doi.org/10.3390/toxins17060282

Vancouver

Rivas M, Pichel M, Zylberman V, Colonna M, Valerio M, Massa C, et al. INM004: Polyclonal Neutralizing Antibodies Against Shiga Toxin as a Treatment for Hemolytic Uremic Syndrome. Toxins. 2025. doi:10.3390/toxins17060282

BibTeX
@article{Rivas2025,
  author = {Rivas, Marta and Pichel, Mariana and Zylberman, Vanesa and Colonna, Mariana and Valerio, Marina and Massa, Carolina and Pardo, Romina and Ciocchini, Andrés E and Sanguineti, Santiago and Roubicek, Ian and Spatz, Linus and Goldbaum, Fernando Alberto},
  title = {INM004: Polyclonal Neutralizing Antibodies Against Shiga Toxin as a Treatment for Hemolytic Uremic Syndrome},
  journal = {Toxins},
  year = {2025},
  doi = {10.3390/toxins17060282}
}
Kostenlos starten →